Frankfurt
01.04.25
09:17 Uhr
0,201 Euro
-0,040
-16,46 %
-16,46 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Alzinova AB: Final results confirm positive phase 1b results with ALZ-101 against Alzheimer's disease | 219 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease... ► Artikel lesen | |
| ALZINOVA Aktie jetzt für 0€ handeln | |||||
| 07.03. | Alzinova AB: Bulletin from the Extraordinary General Meeting of Alzinova AB (publ) | 76 | GlobeNewswire (Europe) | The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg.
Long-term incentive program (LTIP 2025:1 for... ► Artikel lesen | |
| 27.02. | Alzinova AB: Alzinova publishes year-end report 2024 | 110 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December, and the fourth quarter, 2024. The full report, which is attached... ► Artikel lesen | |
| 03.02. | Alzinova AB: All study participants have completed the final visit in the Phase 1 study | 122 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have... ► Artikel lesen | |
| 28.01. | Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase | 247 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's... ► Artikel lesen | |
| 09.12.24 | Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease | 196 | GlobeNewswire (Europe) | ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in... ► Artikel lesen | |
| 14.11.24 | Alzinova AB: Alzinova publishes interim report January - September 2024 | 152 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which... ► Artikel lesen | |
| 10.10.24 | Alzinova's new CEO to "The next six months will be really exciting" | 3 | Cision News | ||
| 22.08.24 | Alzinova AB: Alzinova publishes interim report January - June 2024 | 116 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period April - June, and the first half year, 2024. The full interim report, which is... ► Artikel lesen | |
| 04.06.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Alzinova AB (Record Id 265136) | 500 | GlobeNewswire | With effect from June 05, 2024, the subscription rights in Alzinova AB will be
traded on First North Growth Market. Trading will continue up until and
including June 17, 2024.
Instrument: Subscription... ► Artikel lesen | |
| 30.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.05.2024 | 1.682 | Xetra Newsboard | Das Instrument IWY1 US82655M1071 SIFY TECHNO.LTD.ADR IR 10 EQUITY wird cum Kapitalmassnahme gehandelt am 30.05.2024 und ex Kapitalmassnahme am 31.05.2024 The instrument IWY1 US82655M1071 SIFY TECHNO.LTD.ADR... ► Artikel lesen | |
| 29.05.24 | Alzinova AB: Bulletin from the annual general meeting of Alzinova AB (publ) | 215 | GlobeNewswire (Europe) | Alzinova AB (publ) (the "Company") held its Annual General Meeting on 29 May 2024 in Gothenburg. Below is a summary of the resolutions that were passed. All resolutions were passed with the required... ► Artikel lesen | |
| 28.05.24 | Alzinova AB: Alzinova publishes interim report January - March 2024 | 359 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2024. The full interim report, which is attached in the press release... ► Artikel lesen | |
| 25.04.24 | Alzinova AB: Kristina Torfgård leaves the CEO position at Alzinova AB in July 2024 | 230 | GlobeNewswire (Europe) | Alzinova's CEO Kristina Torfgård has informed the Board of Directors that she wishes to step down as CEO of the company. Kristina will continue to focus on completing the phase 1b clinical study and... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 48,240 | 0,00 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
| PRAXIS PRECISION MEDICINES | 37,870 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| DYNE THERAPEUTICS | 10,460 | 0,00 % | Dyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher - What's Next? | ||
| QIAGEN | 37,205 | +1,45 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,545 | 0,00 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,285 | 0,00 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| ADMA BIOLOGICS | 19,820 | 0,00 % | How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback | ||
| SPRINGWORKS THERAPEUTICS | 44,150 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 29,510 | 0,00 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
| EVOTEC | 6,150 | +1,49 % | Übernahmespekulationen und Kaufempfehlungen: Bayer, BioNTech, Evotec, BioNxt Solutions Aktie | Während bei Evotec derzeit die Übernahmespekulationen pausieren, nehmen sie bei BioNxt Solutions Fahrt auf. Das Unternehmen will in den kommenden 60 Tagen wichtige Meilensteine auf dem Weg zur Vermarktung... ► Artikel lesen | |
| NUVALENT | 70,88 | 0,00 % | Nuvalent-Entwicklungschefin verkauft Aktien im Wert von 292.468 US-Dollar | ||
| BIONTECH | 84,45 | +2,43 % | BioNTech-Aktie: Das ist grotesk! | News von Trading-Treff.de BioNTech ist in einer grotesken Verfassung. Die Mainzer haben immerhin am Dienstag nun einen Aufschlag um fast 0,5 % geschafft. Dabei sind die Notierungen auf 84,45 Euro geklettert.... ► Artikel lesen | |
| IMMUNOVANT | 17,080 | 0,00 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| VERA THERAPEUTICS | 24,020 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| BB BIOTECH | 32,200 | +1,26 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen |
Das Unternehmen ALZINOVA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,201 Euro und damit -16,46 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZINOVA AB finden Sie auf Wallstreet Online.
